乳腺癌组织中maspin和BCSG1蛋白表达及其意义

Expressions and significance of maspin and BCSG1 in breast cancer

目的:探讨maspin和BCSG1蛋白在乳腺癌组织中的表达及其临床意义。方法:应用流式细胞术对94例乳腺癌组织中的maspin和BCSG1蛋白的表达情况进行定量检测,结合临床及病理形态学资料采用t检验、χ2检验、方差分析及直线相关分析讨论maspin和BCSG1蛋白表达的意义。结果:maspin和BCSG1蛋白表达在复发组比无复发组明显增高,且差异有统计学意义(t=-2.86,P=0.0055;t=-2.33,P=0.023);淋巴结转移组比无转移组明显增高,且差异有统计学意义(t=2.91,P=0.004;t=3.42,P=0.001);直线相关分析显示,maspin和BCSG1两者密切相关,r=0.553,P=0.000。在BCSG1的FI值≥4的病例中复发转移病例明显增多(χ2=6.86,P=0.009),但两者均与患者年龄(t=1.129,P=0.262;t=0.808,P=0.421)、肿瘤大小(t=0.078,P=0.938;t=0.002,P=0.998)、临床分期(Fmaspin=0.658,FBCSG1=0.463;Ⅰ和Ⅱ比较:P=0.537,P=0.426;Ⅱ和Ⅲ比较:P=0.458,P=0.371;Ⅰ和Ⅲ比较:P=0.725,P=0.537)无关。结论:BCSG1蛋白可能作为预测乳腺癌预后的参考指标,而maspin蛋白预测乳腺癌预后的价值尚需进一步证实。

OBJECTIVE：To explore the expressions and siginificance of maspin and BCSG1 in breast cancer. METHODS： The flow cytometry method was used to assess the expressions of maspin and BCSG1 in 94 cases of invasive breast cancer. Meanwhile, t-test, Chi-square test, ANOVA and linear correlation were used to analyze the significance between the expression of maspin, BCSG1 and clinical, pathological, prognostic in breast cancer. RESULTS： The high expressions of maspin and BCSG1 of the group of recurrence were significantly higher than those of non-recurrence （t = -2. 86, P= 0. 005 5;t=-2. 33,P=0. 023）. The high expressions of maspin and BCSG1 of the group of lymph nods metastases were significantly higher than those of lymph nods non-metastases （t= 2. 91, P= 0. 004 ; t = 3. 42, P= 0. 001）. The correlation of the expressions was siginificant between maspin and BCSG1, r= 0. 553, P= 0. 000. The recurrent and died cases of FI≥4 of BCSG1 were more than those of FI〈4 , X^2 = 6. 86, P= 0. 009. No siginificant difference was found in the expressions of maspin and BCSG1 with age （t = 1. 129, P = 0. 262;t=0. 808,P=0. 421）, tumor size（t=0. 078,P=0. 938;t= 0.002,P = 0. 998） and clinical stage （Fmaspin= 0. 658, FBCSG1= 0.463;Ⅰ vs Ⅱ：P=0.537, P=0.426;Ⅱ vs Ⅲ：P=0.458, P= 0. 371;Ⅰ vs Ⅲ：P=0. 725, P=0. 537）. CONCLUSION： BCSG1 can be possibly used in the evaluation of the prognosis of breast cancer patients while maspin may not be a suitable indicator.